0000950170-24-018246.txt : 20240221
0000950170-24-018246.hdr.sgml : 20240221
20240221184613
ACCESSION NUMBER: 0000950170-24-018246
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240220
FILED AS OF DATE: 20240221
DATE AS OF CHANGE: 20240221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Albers Jeffrey W.
CENTRAL INDEX KEY: 0001638474
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39460
FILM NUMBER: 24661653
MAIL ADDRESS:
STREET 1: BLUEPRINT MEDICINES CORP.
STREET 2: 215 FIRST STREET, SUITE 340/350
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kymera Therapeutics, Inc.
CENTRAL INDEX KEY: 0001815442
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 812992166
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 ARSENAL YARDS BLVD., SUITE 230
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 857-285-5314
MAIL ADDRESS:
STREET 1: 200 ARSENAL YARDS BLVD., SUITE 230
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
ownership.xml
4
X0508
4
2024-02-20
0001815442
Kymera Therapeutics, Inc.
KYMR
0001638474
Albers Jeffrey W.
C/O KYMERA THERAPEUTICS, INC.
200 ARSENAL YARDS BLVD., SUITE 230
WATERTOWN
MA
02472
true
false
false
false
true
Common Stock
2024-02-20
4
M
false
615
10.34
A
615
D
Common Stock
2024-02-20
4
S
false
615
39.0746
D
0
D
Common Stock
2024-02-21
4
M
false
4385
10.34
A
4385
D
Common Stock
2024-02-21
4
S
false
4385
39.0483
D
0
D
Stock Option (Right to Buy)
10.34
2024-02-20
4
M
false
615
0.00
D
2030-07-28
Common Stock
615
20734
D
Stock Option (Right to Buy)
10.34
2024-02-21
4
M
false
4385
0.00
D
2030-07-28
Common Stock
4385
16349
D
These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $39.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $39.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of July 28, 2020, subject to the reporting person's continued service relationship through each vesting date.
/s/ Bruce N. Jacobs, as Attorney-in-Fact
2024-02-21